Extracellular matrix proteins in organ transplantation

Transplantation

Volumn 69, Issue 12, 2000, Pages 2465-2473

  Coito, Ana J ^a,b   Kupiec Weglinski, Jerzy W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; FIBRONECTIN; SCLEROPROTEIN;

GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0034720743     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200006270-00001     Document Type: Review

References (129)

1. de Sousa M, Tilney NL, Kupiec-Weglinski JW. Recognition of self within self: specific lymphocyte positioning and the extracellular matrix. Immunol Today 1991; 12: 262.
2. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301.
3. Diamond MS, Springer TA. The dynamic regulation of integrin adhesiveness. Curr Biol 1994; 4: 506.
4. Coito AJ, de Sousa M, Kupiec-Weglinski JW. The role of cellular and extracellular matrix adhesion proteins in organ transplantation. Cell Adhes Commun 1994; 2: 249.
5. Hynes RO. Fibronectins. Sci Am 1986; 254: 42.
6. Yamada KM, Aota S, Akiyama SK, LaFlamme SE. Mechanisms of fibronectin and integrin function during cell adhesion and migration. Cold Spring Harb Symp Quant Biol 1992; 57: 203.
7. Hynes RO. Cell adhesion and human disease. Chairman's introduction. Ciba Found Symp 1995; 189: 1.
8. Tamkun JW, Schwarzbauer JE, Hynes RO. A single rat fibronectin gene generates three different mRNAs by alternative splicing of a complex exon. Proc Natl Acad Sci U S A 1984; 81: 5140.
9. Kornblihtt AR, Umezawa K, Vibe-Pedersen K, Baralle FE. Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. EMBO J 1985; 4: 1755.
10. Wayner EA, Garcia-Pardo A, Humphries MJ, McDonald JA, Carter WG. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol 1989; 109: 1321.
11. Vartio T, Laitinen L, Narvanen O, et al. Differential expression of the ED sequence-containing form of cellular fibronectin in embryonic and adult human tissues. J Cell Sci 1987; 88(Pt. 4): 419.
12. Carnemolla B, Balza E, Siri A, et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 1989; 108: 1139.
13. Brown LF, Dubin D, Lavigne L, Logan B, Dvorak HF, Van de Water L. Macrophages and fibroblasts express embryonic fibronectins during cutaneous wound healing. Am J Pathol 1993; 142: 793.
14. French-Constant C, Van de Water L, Dvorak HF, Hynes RO. Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J Cell Biol 1989; 109: 903.
15. Knowlton AA, Connelly CM, Romo GM, Mamuya W, Apstein CS, Brecher P. Rapid expression of fibronectin in the rabbit heart after myocardial infarction with and without reperfusion. J Clin Invest 1992; 89: 1060.
16. Mamuya WS, Brecher P. Fibronectin expression in the normal and hypertrophic rat heart. J Clin Invest 1992; 89: 392.
17. Barnes JL, Torres ES, Mitchell RJ, Peters JH. Expression of alternatively spliced fibronectin variants during remodeling in proliferative glomerulonephritis. Am J Pathol 1995; 147: 1361.
18. Nickeleit V, Zagachin L, Nishikawa K, Peters JH, Hynes RO, Colvin RB. Embryonic fibronectin isoforms are synthesized in crescents in experimental autoimmune glomerulonephritis. Am J Pathol 1995; 147: 965.
19. Schwarzbauer JE. Fibronectin: from gene to protein. Curr Opin Cell Biol 1991; 3: 786.
20. Shimizu Y, van Seventer GA, Horgan KJ, Shaw S. Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J Immunol 1990; 145: 59.
21. Hauzenberger D, Klominek J, Sundqvist KG. Functional specialization of fibronectin-binding beta 1-integrins in T lymphocyte migration. J Immunol 1994; 153: 960.
22. Ybarrondo B, O'Rourke AM, Brian AA, Mescher MF. Contribution of lymphocyte function-associated-1/intercellular adhesion molecule-1 binding to the adhesion/signaling cascade of cytotoxic T lymphocyte activation. J Exp Med 1994; 179: 359.
23. Ostergaard HL, Ma EA. Fibronectin induces phosphorylation of a 120-kDa protein and synergizes with the T cell receptor to activate cytotoxic T cell clones. Eur J Immunol 1995; 25: 252.
24. Hunter AJ, Shimizu Y. Alpha 4 beta 1 integrin-mediated tyrosine phosphorylation in human T cells: characterization of Crk- and Fyn-associated substrates (pp105, pp115, and human enhancer of filamentation-1) and integrin-dependent activation of p59fynl. J Immunol 1997; 159: 4806.
25. Erickson HP. Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. Curr Opin Cell Biol 1993; 5: 869.
26. Oberhauser AF, Marszalek PE, Erickson HP, Fernandez JM. The molecular elasticity of the extracellular matrix protein tenascin. Nature 1998; 393: 181.
27. Chilosi M, Lestani M, Benedetti A, et al. Constitutive expression of tenascin in T-dependent zones of human lymphoid tissues. Am J Pathol 1993; 143: 1348.
28. Erickson HP, Bourdon MA. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol 1989; 5: 71.
29. Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Hook M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin [published erratum appears in J Cell Biol 1992 Feb;116:833]. J Cell Biol 1991; 115: 1127.
30. Ruegg CR, Chiquet-Ehrismann R, Alkan SS. Tenascin, an extracellular matrix protein, exerts immunomodulatory activities. Proc Natl Acad Sci U S A 1989; 86: 7437.
31. Hemesath TJ, Marton LS, Stefansson K. Inhibition of T cell activation by the extracellular matrix protein tenascin. J Immunol 1994; 152: 5199.
32. Hauzenberger D, Olivier P, Gundersen D, Ruegg C. Tenascin-C inhibits betal integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1-5 repeats to fibronectin. Eur J Immunol 1999; 29: 1435.
33. Gundersen D, Tran-Thang C, Sordat B, Mourali F, Ruegg C. Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte- derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering. J Immunol 1997; 158: 1051.
34. Clark RA, Erickson HP, Springer TA. Tenascin supports lymphocyte rolling. J Cell Biol 1997; 137: 755.
35. Timpl R, Rohde H, Robey PG, Rennard SI, Foidart JM, Martin GR. Laminin: a glycoprotein from basement membranes. J Biol Chem 1979; 254: 9933.
36. Martin GR, Timpl R. Laminin and other basement membrane components. Annu Rev Cell Biol 1987; 3: 57.
37. Burgeson RE, Chiquet M, Deutzmann R, et al. A new nomenclature for the laminins. Matrix Biol 1994; 14: 209.
38. Wei J, Shaw LM, Mercurio AM. Integrin signaling in leukocytes: lessons from the alpha6betal integrin. J Leukoc Biol 1997; 61: 397.
39. Kupiec-Weglinski JW, de Sousa M. Lymphocyte traffic is modified in vivo by anti-laminin antibody. Immunology 1991; 72: 312.
40. Lannes-Vieira J, Chammas R, Villa-Verde DM, et al. Extracellular matrix components of the mouse thymic microenvironment. III. Thymic epithelial cells express the VLA6 complex that is involved in laminin-mediated interactions with thymocytes. Int Immunol 1993; 5: 1421.
41. Imhof BA, Ruiz P, Hesse B, Palacios R, Dunon D. EA-1, a novel adhesion molecule involved in the homing of progenitor T lymphocytes to the thymus. J Cell Biol 1991; 114: 1069.
42. Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425.
43. Guan JL, Hynes RO. Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor alpha 4 beta 1. Cell 1990; 60: 53.
44. Hemler ME, Lobb RR. The leukocyte beta 1 integrins. Curr Opin Hematol 1995; 2: 61.
45. Moyano JV, Carnemolla B, Dominguez-Jimenez C, et al. Fibronectin type III5 repeat contains a novel cell adhesion sequence, KLDAPT, which binds activated alpha4betal and alpha4beta7 integrins. J Biol Chem 1997; 272: 24832.
46. Garcia-Pardo A, Wayner EA, Carter WG, Ferreira OCJ. Human B lymphocytes define an alternative mechanism of adhesion to fibronectin. The interaction of the alpha 4 beta 1 integrin with the LHGPEILDVPST sequence of the type III connecting segment is sufficient to promote cell attachment. J Immunol 1990; 144: 3361.
47. Sanchez-Aparicio P, Dominguez-Jimenez C, Garcia-Pardo A. Activation of the alpha 4 beta 1 integrin through the beta 1 subunit induces recognition of the RGDS sequence in fibronectin. J Cell Biol 1994; 126: 271.
48. Klingemann HG, Dedhar S. Distribution of integrins on human peripheral blood mononuclear cells. Blood 1989; 74: 1348.
49. Aota S, Nomizu M, Yamada KM. The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J Biol Chem 1994; 269: 24756.
50. Postigo AA, Sanchez-Mateos P, Lazarovits AI, Sanchez-Madrid F, de Landazuri MO. Alpha 4 beta 7 integrin mediates B cell binding to fibronectin and vascular cell adhesion molecule-1: expression and function of alpha 4 integrins on human B lymphocytes. J Immunol 1993; 151: 2471.
51. Bossy B, Bossy-Wetzel E, Reichardt LF. Characterization of the integrin alpha 8 subunit: a new integrin beta 1- associated subunit, which is prominently expressed on axons and on cells in contact with basal laminae in chick embryos. EMBO J 1991; 10: 2375.
52. Vogel BE, Tarone G, Giancotti FG, Gailit J, Ruoslahti E. A novel fibronectin receptor with an unexpected subunit composition (alpha v beta 1). J Biol Chem 1990; 265: 5934.
53. Poncz M, Eisman R, Heidenreich R, et al. Structure of the platelet membrane glycoprotein lib: homology to the alpha subunits of the vitronectin and fibronectin membrane receptors. J Biol Chem 1987; 262: 8476.
54. Delannet M, Martin F, Bossy B, Cheresh DA, Reichardt LF, Duband JL. Specific roles of the alpha V beta 1, alpha V beta 3 and alpha V beta 5 integrins in avian neural crest cell adhesion and migration on vitronectin. Development 1994; 120: 2687.
55. Robert C, Fuhlbrigge RC, Kieffer JD, et al. Interaction of dendritic cells with skin endothelium: a new perspective on immunosurveillance. J Exp Med 1999; 189: 627.
56. Nishimura SL, Sheppard D, Pytela R. Integrin alpha v beta 8. Interaction with vitronectin and functional divergence of the beta 8 cytoplasmic domain. J Biol Chem 1994; 269: 28708.
57. Shaw LM, Mercurio AM Regulation of alpha 6 beta 1 integrin-mediated migration in macrophages. Agents Actions Suppl 1995; 47: 101.
58. Bohnsack JF, Akiyama SK, Damsky CH, Knape WA, Zimmerman GA. Human neutrophil adherence to laminin in vitro: evidence for a distinct neutrophil integrin receptor for laminin. J Exp Med 1990; 171: 1221.
59. Shimizu Y, van Seventer GA, Horgan KJ, Shaw S. Regulated expression and binding of three VLA (beta 1) integrin receptors on T cells. Nature 1990; 345: 250.
60. Shimizu Y, van Seventer GA, Ennis E, Newman W, Horgan KJ, Shaw S. Crosslinking of the T cell-specific accessory molecules CD7 and CD28 modulates T cell adhesion. J Exp Med 1992; 175: 577.
61. Shimizu Y, Mobley JL, Finkelstein LD, Chan AS. A role for phosphatidylinositol 3-kinase in the regulation of beta 1 integrin activity by the CD2 antigen. J Cell Biol 1995; 131: 1867.
62. Chan AS, Mobley JL, Fields GB, Shimizu Y. CD7-mediated regulation of integrin adhesiveness on human T cells involves tyrosine phosphorylation-dependent activation of phosphatidylinositol 3-kinase. J Immunol 1997; 159: 934.
63. Weber C, Alon R, Moser B, Springer TA. Sequential regulation of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity by CC chemokines in monocytes: implications for transendothelial chemotaxis. J Cell Biol 1996; 134: 1063.
64. Carr MW, Alon R, Springer TA. The C-C chemokine MCP-1 differentially modulates the avidity of beta 1 and beta 2 integrins on T lymphocytes. Immunity 1996; 4: 179.
65. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 1994; 91: 3652.
66. LaFlamme SE, Akiyama SK, Yamada KM. Regulation of fibronectin receptor distribution [published erratum appears in J Cell Biol 1992 July;118: 491]. J Cell Biol 1992; 117: 437.
67. Delcommenne M, Streuli CH. Control of integrin expression by extracellular matrix. J Biol Chem 1995; 270: 26794.
68. Gorski A, Mrowiec T, Paczek L, Stepien-Sopniewska B. Abnormal T-cell costimulation by proteins of the extracellular matrix in human renal allografting. Res Immunol 1993; 144: 305.
69. Mueller AR, Platz KP, Gebauer B, et al. Changes at the extracellular matrix during acute and chronic rejection in human liver transplantation. Transpl Int 1998; 11 (suppl 1): S377.
70. Demirci G, Nashan B, Pichlmayr R. Fibrosis in chronic rejection of human liver allografts: expression patterns of transforming growth factor-TGFbetal and TGF-beta3. Transplantation 1996; 62: 1776.
71. Abrass CK, Berfield AK, Stehman-Breen C, Alpers CE, Davis CL. Unique changes in interstitial extracellular matrix composition are associated with rejection and cyclosporine toxicity in human renal allograft biopsies [see comments]. Am J Kidney Dis 1999; 33: 11.
72. Coito AJ, Binder J, de Sousa M, Kupiec-Weglinski JW. The expression of extracellular matrix proteins during accelerated rejection of cardiac allografts in sensitized rats. Transplantation 1994; 57: 599.
73. Coito AJ, Brown LF, Peters JH, Kupiec-Weglinski JW, Van de Water L. Expression of fibronectin splicing variants in organ transplantation: a differential pattern between rat cardiac allografts and isografts. Am J Pathol 1997; 150: 1757.
74. Coito AJ, Binder J, Brown LF, de Sousa M, Van de Water L, Kupiec-Weglinski JW. Anti-TNF-alpha treatment down-regulates the expression of fibronectin and decreases cellular infiltration of cardiac allografts in rats. J Immunol 1995; 154: 2949.
75. Coito AJ, Kupiec-Weglinski JW. Extracellular matrix proteins: bystanders or active participants in the allograft rejection cascade? Ann Transplant 1996; 1: 14.
76. Roberts CJ, Birkenmeier TM, McQuillan JJ, et al. Transforming growth factor beta stimulates the expression of fibronectin and of both subunits of the human fibronectin receptor by cultured human lung fibroblasts. J Biol Chem 1988; 263: 4586.
77. Ignotz RA, Endo T, Massague J. Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. J Biol Chem 1987; 262: 6443.
78. Clausell N, Molossi S, Rabinovitch M. Increased interleukin-1 beta and fibronectin expression are early features of the development of the postcardiac transplant coronary arteriopathy in piglets. Am J Pathol 1993; 142: 1772.
79. Molossi S, Clausell N, Rabinovitch M. Reciprocal induction of tumor necrosis factor-alpha and interleukin-1 beta activity mediates fibronectin synthesis in coronary artery smooth muscle cells. J Cell Physiol 1995; 163: 19.
80. Clausell N, Molossi S, Sett S, Rabinovitch M. In vivo blockade of tumor necrosis factor-alpha in cholesterol-fed rabbits after cardiac transplant inhibits acute coronary artery neointimal formation. Circulation 1994; 89: 2768.
81. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650.
82. Clark RA, Dvorak HF, Colvin RB. Fibronectin in delayed-type hypersensitivity skin reactions: associations with vessel permeability and endothelial cell activation. J Immunol 1981; 126: 787.
83. Grinnell F, Billingham RE, Burgess L. Distribution of fibronectin during wound healing in vivo. J Invest Dermatol 1981; 76: 181.
84. Jarnagin WR, Rockey DC, Koteliansky VE, Wang SS, Bissell DM. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 1994; 127: 2037.
85. Coito AJ, Onodera K, Kupiec-Weglinski JW. Distinct roles of fibronectin expression by endothelial cells and macrophages in the infectious tolerance pathway in allograft recipients. Surg Forum 1998; 373.
86. Matsuyama T, Yamada A, Kay J, et al. Activation of CD4 cells by fibronectin and anti-CD3 antibody: a synergistic effect mediated by the VLA-5 fibronectin receptor complex. J Exp Med 1989; 170: 1133.
87. Nojima Y, Rothstein DM, Sugita K, Schlossman SF, Morimoto C. Ligation of VLA-4 on T cells stimulates tyrosine phosphorylation of a 105-kD protein. J Exp Med 1992; 175: 1045.
88. Ticchioni M, Deckert M, Bernard G, et al. Comitogenic effects of very late activation antigens on CDS-stimulated human thymocytes: involvement of various tyrosine kinase pathways. J Immunol 1995; 154: 1207.
89. Yamada A, Nikaido T, Nojima Y, Schlossman SF, Morimoto C. Activation of human CD4 T lymphocytes: interaction of fibronectin with VLA-5 receptor on CD4 cells induces the AP-1 transcription factor. J Immunol 1991; 146: 53.
90. McCarthy JB, Vachhani BV, Wahl SM, Finbloom DS, Feldman GM. Human monocyte binding to fibronectin enhances IFN-gamma-induced early signaling events. J Immunol 1997; 159: 2424.
91. Brunmark A, O'Rourke AM. Augmentation of mature CD4+ T cell responses to isolated antigenic class II proteins by fibronectin and intercellular adhesion rnolecule-1. J Immunol 1997; 159: 1676.
92. Hershkoviz R, Gilat D, Miron S, et al. Extracellular matrix induces tumour necrosis factor-alpha secretion by an interaction between resting rat CD4+ T cells and macrophages. Immunology 1993; 78: 50.
93. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-betal in vivo. Cell 1998; 93: 1159.
94. Lortat-Jacob H, Grimaud JA. Interferon-gamma C-terminal function: new working hypothesis. Heparan sulfate and heparin, new targets for IFN-gamma, protect, relax the cytokine and regulate its activity. Cell Mol Biol 1991; 37: 253.
95. Lortat-Jacob H, Kleinman HK, Grimaud JA. High-affinity binding of interferon-gamma to a basement membrane complex (matrigel). J Clin Invest 1991; 87: 878.
96. Bottinger EP, Factor VM, Tsang ML, et al. The recombinant proregion of transforming growth factor betal (latency- associated peptide) inhibits active transforming growth factor betal in transgenic mice. Proc Natl Acad Sci U S A 1996; 93: 5877.
97. Laine J, Etelamaki P, Holmberg C, Dunkel L. Apoptotic cell death in human chronic renal allograft rejection. Transplantation 1997; 63: 101.
98. Bergese SD, Klenotic SM, Wakely ME, Sedmak DD, Orosz CG. Apoptosis in murine cardiac grafts. Transplantation 1997; 63: 320.
99. Onodera K, Hancock WW, Graser E, et al. Type 2 helper T cell-type cytokines and the development of "infectious" tolerance in rat cardiac allograft recipients. J Immunol 1997; 158: 1572.
100. Akyurek LM, Johnsson C, Lange D, et al. Tolerance induction ameliorates allograft vasculopathy in rat aortic transplants: influence of Fas-mediated apoptosis. J Clin Invest 1998; 101: 2889.
101. Meredith JEJ, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993; 4: 953.
102. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995; 267: 891.
103. Zhang Z, Vuori K, Reed JC, Ruoslahti E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci U S A 1995; 92: 6161.
104. Matter ML, Zhang Z, Nordstedt C, Ruoslahti E. The alpha5beta1 integrin mediates elimination of amyloid-beta peptide and protects against apoptosis. J Cell Biol 1998; 141: 1019.
105. Rich S, Van Nood N, Lee HM. Role of alpha 5 beta 1 integrin in TGF-beta 1-costimulated CD8+ T cell growth and apoptosis. J Immunol 1996; 157: 2916.
106. Hines KL, Kulkarni AB, McCarthy JB, et al. Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor beta 1 knockout mice. Proc Natl Acad Sci U S A 1994; 91: 5187.
107. Wahl SM, Allen JB, Hines KL, et al. Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment. J Clin Invest 1994; 94: 655.
108. Coito AJ, Korom S, Graser E, Volk HD, Van de Water L, Kupiec-Weglinski JW. Blockade of very late antigen-4 integrin binding to fibronectin in allograft recipients: I. Treatment with connecting segment-1 peptides prevents acute rejection by suppressing intragraft mononuclear cell accumulation, endothelial activation, and cytokine expression. Transplantation 1998; 65: 699.
109. Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990; 60: 577.
110. Makarem R, Newham P, Askari JA, et al. Competitive binding of vascular cell adhesion molecule-1 and the HepII/IIICS domain of fibronectin to the integrin alpha 4 beta 1. J Biol Chem 1994; 269: 4005.
111. Orosz CG, Ohye RG, Pelletier RP, et al. Treatment with antivascular cell adhesion molecule 1 monoclonal antibody induces long-term murine cardiac allograft acceptance. Transplantation 1993; 56: 453.
112. Tice DG, Bruch D, Ikramuddin S. Anti-VLA-4 and cyclosporine synergistically prolong rat heterotopic small bowel allografts. Transplant Proc 1996; 28: 2496.
113. Suzuki J, Isobe M, Izawa A, et al. Differential Th1 and Th2 cell regulation of murine cardiac allograft acceptance by blocking cell adhesion of ICAM-1/LFA-1 and VCAM-1/VLA-4. Transpl Immunol 1999; 7: 65.
114. Yang H, Issekutz TB, Wright JRJ. Prolongation of rat islet allograft survival by treatment with monoclonal antibodies against VLA-4 and LFA-1. Transplantation 1995; 60: 71.
115. Stegall MD, Elices M, Pietra W, Shepard G, Gup C, Gill RG. Different roles for alpha 4-integrin/VCAM-1 and alpha 4/fibronectin interactions in allograft rejection. Transplant Proc 1999; 31: 786.
116. Korom S, Hancock WW, Coito AJ, Kupiec-Weglinski JW. Blockade of very late antigen-4 integrin binding to fibronectin in allograft recipients. II. Treatment with connecting segment-1 peptides prevents chronic rejection by attenuating arteriosclerotic development and suppressing intragraft T cell and macrophage activation. Transplantation 1998; 65: 854.
117. Wasowska B, Wieder KJ, Hancock WW, et al. Cytokine and alloantibody networks in long term cardiac allografts in rat recipients treated with rapamycin. J Immunol 1996; 156: 395.
118. Molossi S, Elices M, Arrhenius T, Diaz R, Coulber C, Rabinovitch M. Blockade of very late antigen-4 integrin binding to fibronectin with connecting segment-1 peptide reduces accelerated coronary arteriopathy in rabbit cardiac allografts [see comments]. J Clin Invest 1995; 95: 2601.
119. Rodriguez RM, Pitzalis C, Kingsley GH, Henderson E, Humphries MJ, Panayi GS. T lymphocyte adhesion to fibronectin (FN): a possible mechanism for T cell accumulation in the rheumatoid joint. Clin Exp Immunol 1992; 89: 439.
120. Wieder KJ, Hancock WW, Schmidbauer G, et al. Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-gamma in rat recipients of cardiac allografts. J Immunol 1993; 151: 1158.
121. Schmidbauer G, Hancock WW, Wasowska B, Badger AM, Kupiec-Weglinski JW. Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cell activation, cytokine production, and cell adhesion. Transplantation 1994; 57: 933.
122. de Sousa M. Lymphocyte traffic and positioning in vivo: an expanded role for the ECM, the VLA proteins and the cytokines. Pathol Res Pract 1994; 190; 840.
123. dos Santos SR, Rossi MA, Laus JL, Silva JS, Savino W, Mengel J. Anti-CD4 abrogates rejection and reestablishes long-term tolerance to syngeneic newborn hearts grafted in mice chronically infected with Trypanosoma cruzi. J Exp Med 1992; 175: 29.
124. Silva-Barbosa SD, Cotta-de-Almeida V, Riederer I, et al. Involvement of laminin and its receptor in abrogation of heart graft rejection by autoreactive T cells from Trypanosoma cruziinfected mice. J Immunol 1997; 159: 997.
125. Seiter S, Weber B, Tilgen W, Zoller M. Down-modulation of host reactivity by anti-CD44 in skin transplantation. Transplantation 1998; 66: 778.
126. Knoflach A, Magee C, Denton MD, et al. Immunomodulatory functions of hyaluronate in the LEW-to-F344 model of chronic cardiac allograft rejection. Transplantation 1999; 67: 909.
127. DeGrendele HC, Estess P, Picker LJ, Siegelman MH. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway. J Exp Med 1996; 183: 1119.
128. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997; 278: 672.
129. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998; 152: 353.